Results 221 to 230 of about 29,153 (282)
Myelin dysfunction in aging and brain disorders: mechanisms and therapeutic opportunities. [PDF]
Huang Z+4 more
europepmc +1 more source
Developing muscarinic receptor M1 classification models utilizing transfer learning and generative AI techniques. [PDF]
Dey S, Wallqvist A, AbdulHameed MDM.
europepmc +1 more source
The potential of repurposing clemastine to promote remyelination. [PDF]
Yamazaki R, Ohno N.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
European Journal of Neuroscience, 2020
Acetylcholine (ACh) modulates neurotransmitter release in the central nervous system. Although GABAergic transmission onto the striatal cholinergic interneurons (ChIN) is modulated by dopamine receptors, cholinergic modulation of the same synapse is ...
Etsuko Suzuki, T. Momiyama
semanticscholar +1 more source
Acetylcholine (ACh) modulates neurotransmitter release in the central nervous system. Although GABAergic transmission onto the striatal cholinergic interneurons (ChIN) is modulated by dopamine receptors, cholinergic modulation of the same synapse is ...
Etsuko Suzuki, T. Momiyama
semanticscholar +1 more source
Involvement of M1-muscarinic receptors in the excitation of neocortical neurones by acetylcholine
Neuropharmacology, 1987The technique of microelectrophoresis was used to investigate the cholinoceptor pharmacology of spontaneously active single neurones in the parietal cortex of the rat. Acetylcholine, carbachol and the selective M1-muscarinic receptor agonist, McN-A-343, were each potent excitants (rank order of apparent potency: carbachol greater than acetylcholine ...
C. M. Bradshaw+2 more
openaire +3 more sources
Autoantibodies against M1 muscarinic acetylcholine receptor in myasthenic disorders
European Journal of Neurology, 2007The Lambert–Eaton myasthenic syndrome (LEMS), often associated with small‐cell lung carcinoma (SCLC), is a disorder of acetylcholine (ACh) release from motor nerve terminals. In most patients, it is caused by autoantibodies against the P/Q‐type voltage‐gated calcium channels (VGCC) that trigger ACh release. However, these antibodies are not detected in
Hiroaki Yoshikawa+3 more
openaire +3 more sources